European Union - English - EMA (European Medicines Agency)

ecuphar - meloxicam - anti inflammatory and antirheumatic products - dogs; cats - oral suspension:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.solution for injection:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.cats:reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - topotecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

virbac s.a. - leishmania infantum excreted secreted proteins - immunologicals - dogs - for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with leishmania infantum.the efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity: 1 year after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psychoanaleptics - dogs - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - hydrocortisone aceponate - corticosteroids, dermatological preparations - dogs - for symptomatic treatment of inflammatory and pruritic dermatoses in dogs.for alleviation of clinical signs associated with atopic dermatitis in dogs.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 felv-envelope antigen - inactivated viral vaccines, feline leukaemia virus, immunologicals for felidae, - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - osaterone acetate - urologicals - dogs - treatment of benign prostatic hypertrophy (bph) in male dogs.